Expression of GLUT1 in primary renal tumors: Morphologic and biologic implications

American Journal of Clinical Pathology

Volumn 128, Issue 2, 2007, Pages 245-254

  Ozcan, Ayhan ^a   Shen, Steven S ^a,c   Zhai, Qihui ^a,c   Truong, Luan D ^a,b,c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

GLUT1; Immunohistochemistry; Renal neoplasm; Tissue microarray; Transitional cell carcinoma; Western blot

Indexed keywords

GLUCOSE TRANSPORTER 1;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; ONCOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NEOPLASM STAGING;

EID: 34547909267     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/HV6NJVRQKK4QHM9F     Document Type: Article

References (37)

1. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-662.
2. Page T, Hodgkinson AD, Ollerenshaw M, et al. Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet. 2005;163:151-155.
3. Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci. 1999;14:105-110.
4. Faramarz IB. Metabolic regulation of glucose transport. J Membr Biol. 1993;135:1-10.
5. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J Biol Chem. 1995;270:29083-29089.
6. Nishioka T, Oda Y, Seino Y, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res. 1992;52:3972-3979.
7. Nagase Y, Takata K, Moriyama N, et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol. 1995;153:798-801.
8. Baer SC, Casaubon L, Younes M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol. 1997;37:575-577.
9. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer. 1997;74:189-192.
10. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.
11. Wang BY, Kalir T, Sabo E, et al. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer. 2000;88:2774-2781.
12. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-641.
13. Kang SS, Chun YK, Hur MH, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002;93:1123-1128.
14. Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144-1150.
15. Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F- fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 2003;23:3263-3272.
16. Rudlowski C, Becker AJ, Schroder W, et al. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol. 2003;120:691-698.
17. Ozcan A, Deveci MS, Oztas E, et al. The prognostic value of GLUT-1 expression in ovarian surface epithelial tumors (a morphometric study). Anal Quant Cytol Histol. 2005;27:181-186.
18. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta. 1974;355:77-104.
19. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
20. Binder C, Binder L, Marx D, et al. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 1997;17:4299-4304.
21. Ahmed N, Berridge MV. Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: contrasting effects of oncogenes and heat stress in a murine marrow-derived cell line. Life Sci. 1998;63:1887-1903.
22. Ito S, Fukusato T, Nemoto T, et al. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002;94:1080-1091.
23. Beaney RP. Positron emission tomography in the study of human tumors. Semin Nucl Med. 1984;14:324-341.
24. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
25. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778-1785.
26. Miyakita H, Tokunaga M, Onda H, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15-18.
27. Younes M, Brown RW, Mody DR, et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995,15:2895-2898.
28. Noguchi Y, Saito A, Miyagi Y, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 2000;154:175-182.
29. Kim YW, Do IG, Park YK. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract. 2006;202:759-765.
30. Idrees MT, Schlosshauer P, Li G, et al. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. Histopathology. 2006;49:75-81.
31. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
32. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982.
33. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol. 2000;113:171-175.
34. Chang S, Lee S, Lee C, et al. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 2000;55:448-552.
35. Briasoulis E, Judson I, Pavlidis N, et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol. 2000;18:3535-3544.
36. Zhang M, Zhang Z, Blessington D, et al. Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters. Bioconjug Chem. 2003;14:709-714.
37. Singh A, Purohit A, Hejaz HA, et al. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-0- sulfamate. Mol Cell Endocrinol. 2000;160:61-66.